FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
This article was originally published in The Tan Sheet
Executive Summary
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers
You may also be interested in...
Antihistamine Forced Switch Proposal Returns In Citizen Petition
A law firm seeks to cut its own health care costs as well as direct FDA's attention to previous citizen petitions to switch Rx antihistamines to OTC with a petition asking FDA to switch Sanofi-Aventis's Allegra and Pfizer's Zyrtec
Antihistamine Forced Switch Proposal Returns In Citizen Petition
A law firm seeks to cut its own health care costs as well as direct FDA's attention to previous citizen petitions to switch Rx antihistamines to OTC with a petition asking FDA to switch Sanofi-Aventis's Allegra and Pfizer's Zyrtec
Antihistamine Forced Switch Proposal Returns In Citizen Petition
A law firm seeks to cut its own health care costs as well as direct FDA's attention to previous citizen petitions to switch Rx antihistamines to OTC with a petition asking FDA to switch Sanofi-Aventis's Allegra and Pfizer's Zyrtec